
FIGURE 1

ITT = intent-to-treat population (patients who received ≥1 dose of study medication); CE = clinically evaluable population (ITT patients who received ≥80% of prescribed study medication and no effective non-study antibiotics during study, with adequate follow-up); amino/β-Ll = aminopenicillins/ β-lactamase inhibitors.


FIGURE 2
Clinical outcome by primary infection-type diagnosis at test of cure in the intent-to-treat population
Linezolid n=241
Amino/β-LI n=120
Clinical Cure (%)
100
90
80
70
60
50
40
30
20
10
0
81.4†
67.9
79.1
74.1
62.5
57.1
91.7
81.8
100
100
69.0
61.0
(n=161)
(n=84)
(n=86)
(n=54)
(n=32)
(n=14)
(n=12)
(n=11)
(n=5)
(n=1)
(n=44)
(n=16)
Infected Ulcer
Cellulitis
Deep Soft Tissue Infection
Paronychia
Abscess
Osteomyelitis
Amino/ β-LI = aminopenicillins/β-lactamase inhibitors.